Valuation: Lotus Pharmaceuticals, Inc.

Market Cap 9.74M 8.44M 7.9M 7.21M 13.56M 929M 13.79M 92.61M 36.29M 465M 36.55M 35.76M 1.55B P/E 2009
3.88x
P/E 2010 4.84x
Enterprise Value 14.38M 12.46M 11.67M 10.65M 20.03M 1.37B 20.37M 137M 53.6M 687M 54M 52.83M 2.29B EV / Sales 2009
1.02x
EV / Sales 2010 0.95x
Free-Float
99%
Yield 2009 *
-
Yield 2010 -
Manager TitleAgeSince
Chief Executive Officer - -
Director TitleAgeSince
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+41.51%-18.92% - - 7.93M
-0.12%-1.09%+22.38%+68.83% 48.92B
-1.14%+9.22%+60.80%+124.81% 41.53B
-0.32%-0.77%-1.53%+16.21% 12.43B
+6.43%+6.24%+27.22%+81.04% 11.7B
+0.77%-0.38%+30.98%+137.44% 9.09B
+1.95%+9.30%+24.43%+40.59% 7.4B
+1.62%+3.49%+41.67%-13.45% 7.15B
+1.10%+2.06%+12.70%+180.85% 6.66B
-1.22%+7.23%-25.51%+28.75% 5.95B
Average +5.06%+3,738.12%+21.46%+73.90% 16.76B
Weighted average by Cap. +0.34%+5,024.23%+30.58%+83.06%

Financials

2009 2010
Net sales 57.82M 50.11M 46.91M 42.8M 80.55M 5.52B 81.9M 550M 216M 2.76B 217M 212M 9.21B 72.7M 63M 58.98M 53.81M 101M 6.93B 103M 692M 271M 3.47B 273M 267M 11.58B
Net income 16.43M 14.24M 13.33M 12.16M 22.89M 1.57B 23.27M 156M 61.24M 784M 61.7M 60.35M 2.62B 14.42M 12.5M 11.7M 10.68M 20.09M 1.38B 20.43M 137M 53.76M 689M 54.16M 52.98M 2.3B
Net Debt 5.29 4.59 4.29 3.92 7.37 504.92 7.5 50.36 19.73 252.73 19.88 19.44 843.14 4.65 4.03 3.77 3.44 6.47 443.2 6.58 44.2 17.32 221.83 17.45 17.07 740.08
Logo Lotus Pharmaceuticals, Inc.
Lotus Pharmaceuticals Inc is a company mainly engaged in development, manufacture, and sales of pharmaceuticals. The Company produces crude medicine and drugs in forms of tablets, capsules, granules, eye-drops, and freeze-dried powder injection. The Company's drug development is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. The Company operated in two business segment Wholesales segment and Retail segment. The Company's products include Maixin-valsartan capsules for the treatment of hypertension, Muxineye drops for the treatment of glaucoma and Yipubishan-octreotide Acetate Injection solution for the treatment of gastric ulcers. The Company mainly conducts its businesses in the domestic market and overseas markets.
Employees
-